MedTrace Logo

Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures

NCT00537940 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 482

Last updated 2021-01-22

Study results available
· View outcomes & findings →

Summary

To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.

Conditions

  • Epilepsy
  • Partial Seizure Disorder
  • Epilepsies, Partial
  • Complex Partial Seizure Disorder

Interventions

DRUG

Pregabalin

150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects

DRUG

Gabapentin

300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Costa Rica
  • El Salvador
  • Guatemala
  • Peru

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00537940 on ClinicalTrials.gov